We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




First Of Its Kind Measles Antibody Test Validated for Use with Dried Blood Spot Samples

By LabMedica International staff writers
Posted on 04 Mar 2025

Measles is a highly contagious airborne disease that can lead to serious complications for those infected. With the number of measles cases increasing worldwide, expanding and improving access to testing for the measles virus is crucial for enhancing surveillance and prevention efforts. Now, a novel assay supports the diagnosis of a measles virus infection and also determines the immune status against measles virus, with validation for dried blood spots (DBS) as well as serum and plasma samples.

Revvity, Inc. (Waltham, MA, USA) has launched EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG), designed to assist in diagnosing measles virus infections or determining immunity to the virus. The Anti-Measles Virus ELISA 2.0 (IgG) is the first in a series of assays being developed by EUROIMMUN to expand its portfolio of serological infection diagnostics, now including validation for DBS in addition to serum and plasma. The use of DBS in diagnostics only requires a few drops of capillary blood to produce reliable test results. The blood is typically obtained from the fingertip, placed on a paper card, and then sent to a diagnostic lab for analysis.

The minimally invasive sampling method and the high stability of DBS make this diagnostic approach advantageous for routine testing, research studies, or in areas with limited medical infrastructure. By enabling the use of DBS rather than traditional venous blood samples, this innovation increases accessibility for healthcare practitioners and diagnostic labs investigating measles virus infections. The Anti-Measles Virus ELISA 2.0 (IgG) can be processed either manually or automatically with EUROIMMUN’s scalable solutions designed for DBS processing and ELISA.

“Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution,” said Dr. Lars Komorowski, chief scientific officer of EUROIMMUN.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics

With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.